Sign inCreate account

Report workspace

Add to folder
NCT03811509UNKNOWNanonymous

Study for Improving Life Quality in Breast Cancer Women Treated With Aromatase Inhibitors: Cohort B-ABLE

Sponsor

Source record

Parc de Salut Mar

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

bisphosphonate

Indication / condition

AI-normalized

Osteoporosis

Intervention

Source record

bisphosphonate

Related intelligence directories

Indication directory: OsteoporosisModality directory: small moleculeTarget directory: bisphosphonate

Source & freshness

Source record

NCT ID

NCT03811509

Original source

ClinicalTrials.gov

Source last updated

Jan 28, 2019

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03811509

Title

Study for Improving Life Quality in Breast Cancer Women Treated With Aromatase Inhibitors: Cohort B-ABLE

Sponsor

Parc de Salut Mar

Status

UNKNOWN

Phase

PHASE4

Condition raw

Osteoporosis, Osteoporosis Fracture, Arthralgia Generalized

Condition normalized

Osteoporosis, Osteoporosis Fracture, Arthralgia Generalized

Modality raw

small molecule

Modality normalized

small molecule

Target raw

bisphosphonate

Target normalized

bisphosphonate

Interventions

bisphosphonate

Public preview

Source record

The main objective of the study is to improve the life quality of women treated with AI. Cohort B-ABLE is designed to evaluate musculoskeletal events derived of using AI in breast cancer women. The project objectives are the analysis of the AI deleterious effect on bone microarchitecture and early determination of the risk of fragility fracture with dual energy x-ray absorptiometry (DEXA), lumbar spine Rx, Trabecular Bone Score (TBS) and microindentation. Determination of physiological causes of the AI-related arthralgia by analyzing joint degradation markers, steroid hormone levels remaining in blood and functional magnetic resonance, before and after three months of AI treatment

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Study for Improving Life Quality in Breast Cancer Women Treated With Aromatase Inhibitors: Cohort B-ABLE

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT03811509

Status

UNKNOWN

Phase

PHASE4

Sponsor

Parc de Salut Mar

Executive brief

Investment-Ready Snapshot

The main objective of the study is to improve the life quality of women treated with AI. Cohort B-ABLE is designed to evaluate musculoskeletal events derived of using AI in breast cancer women. The project objectives are the analysis of the AI deleterious effect on bone microarchitecture and early determination of the risk of fragility fracture with dual energy x-ray absorptiometry (DEXA), lumbar spine Rx, Trabecular Bone Score (TBS) and microindentation. Determination of physiological causes of the AI-related arthralgia by analyzing joint degradation markers, steroid hormone levels remaining in blood and functional magnetic resonance, before and after three months of AI treatment

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 28, 2019
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03811509

Indication

Osteoporosis

Modality

small molecule

Target

bisphosphonate

Intervention

bisphosphonate

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.